88888888 ...

Core Insights - The article presents a ranking of 78 unprofitable biotechnology companies listed in Hong Kong, highlighting their market capitalizations and stock prices as of October 31, 2025 [1][2][3]. Market Capitalization Summary - The top three companies by market capitalization are: 1. 名要放田 (Ming Yao Fang Tian) with a market cap of HKD 286.26 billion 2. 信达生物 (Innovent Biologics) with a market cap of HKD 149.08 billion 3. 科伦博泰生物-B (Kintor Pharmaceutical) with a market cap of HKD 104.47 billion [1][2]. Price Performance Summary - The highest price increase for the year is observed in: 1. 北海康成-B (Beihai Kangcheng) with a price increase of 1381.20% 2. 药康安康 - B (Yao Kang An Kang) with a price increase of 1297.72% 3. 三叶草生物-B (San Ye Cao) with a price increase of 812.86% [3][4]. Additional Performance Insights - Other notable performers include: - 德棋医药-B (Deqi Pharmaceutical) with a 696.92% increase - 和铂失药-B (He Bo Shi Yao) with a 624.19% increase - 荣昌生物 (Rongchang Biologics) with a 525.00% increase [3][4]. Overall Trends - The article indicates a significant volatility in the biotechnology sector, with many companies experiencing substantial price fluctuations, reflecting investor sentiment and market dynamics [3][4].

中国经济网北京11月7日讯 君实生物(688180.SH)今日收报37.79元，跌幅1.92%。该股目前处于破发 状态。 经计算，君实生物两次募集资金合计86.12亿元。 2016年至2024年，君实生物归属于上市公司股东的净利润分别为-1.35亿元、-3.17亿元、-7.23亿 元、-7.47亿元、-16.69亿元、-7.21亿元、-23.88亿元、-22.83亿元、-12.81亿元；归属于上市公司股东的 扣除非经常性损益的净利润分别为-1.60亿元、-3.00亿元、-7.06亿元、-7.76亿元、-17.09亿元、-8.84亿 元、-24.50亿元、-22.98亿元、-12.90亿元。 2025年前三季度，公司实现营业收入18.06亿元，同比增长42.06%；归属于上市公司股东的净利润 为-5.96亿元，上年同期为-9.27亿元；归属于上市公司股东的扣非净利润为-6.7亿元，上年同期为-9.4亿 元；经营活动产生的现金流量净额为-3.43亿元，上年同期为-11.13亿元。 （责任编辑：关婧） 君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿 元，较原计划多1 ...

来源：新浪基金∞工作室 11月7日，君实生物跌1.92%，截至发稿，报37.79元/股，成交2.92亿元，换手率1.00%，总市值387.99亿 元。君实生物股价已经连续5天下跌，区间累计跌幅6.39%。 截至发稿，李会忠累计任职时间11年116天，现任基金资产总规模2.33亿元，任职期间最佳基金回报 70.73%， 任职期间最差基金回报-39.92%。 王毕功累计任职时间361天，现任基金资产总规模9416.11万元，任职期间最佳基金回报1.11%， 任职期 间最差基金回报0.73%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 从基金十大重仓股角度 数据显示，格林基金旗下1只基金重仓君实生物。格林鑫悦一年持有期混合A（011775）三季度持有股 数3.3万股，占基金净值比例为1.45%，位居第九大重仓股。根据测算，今日浮亏损失约2.44万元。连续 5天下跌期间浮亏损失8.51万元。 格林鑫悦一年持有期混合A（011775）成立日期2021年6月9日，最新规模573 ...

来源：新浪基金∞工作室 11月7日，君实生物跌1.92%，截至发稿，报37.79元/股，成交2.92亿元，换手率1.00%，总市值387.99亿 元。君实生物股价已经连续5天下跌，区间累计跌幅6.39%。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0.59%。 成曦累计任职时间9年187天，现任基金资产总规模2501.21亿元，任职期间最佳基金回报131.04%， 任 职期间最差基金回报-67.89%。 从君实生物十大流通股东角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 易方达上证科创板50ETF（58 ...

来源：新浪基金∞工作室 11月7日，君实生物跌1.92%，截至发稿，报37.79元/股，成交2.92亿元，换手率1.00%，总市值387.99亿 元。君实生物股价已经连续5天下跌，区间累计跌幅6.39%。 资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售90.67%，技术许可及特许权使用收入8.74%，技术服务及其他 0.59%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 前海联合国民健康混合A（003581）成立日期2016年12月29日，最新规模1564.76万。今年以来收益 6.95%，同类排名6475/8148；近一年收益0.76%，同类排名7710/8053；成立以 ...

Core Viewpoint - The company, Junshi Biosciences, aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation in drug development [2][3]. Company Overview - Junshi Biosciences was founded on December 27, 2012, and went public on July 15, 2020. Its main business involves the research and commercialization of monoclonal antibody drugs and other therapeutic proteins, with 90.67% of revenue coming from drug sales [7]. - As of September 30, 2025, the company reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [8]. Product Development - The company has developed a strong portfolio of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi Biosciences is also advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Collaborations and Research - The company is collaborating with institutions such as Peking University and the Chinese Academy of Sciences to develop vaccines, including a monkeypox vaccine, which is currently in the preclinical development stage [3][8]. Market Performance - On November 7, the company's stock fell by 1.92%, with a trading volume of 292 million yuan and a market capitalization of 38.799 billion yuan [1]. - The stock has seen a net outflow of 458.376 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 41.33 yuan, with the current price approaching a resistance level of 38.99 yuan, suggesting potential volatility in the near term [6].

Core Viewpoint - Junshi Biosciences experienced a slight decline in stock price, with significant trading activity in both margin financing and securities lending, indicating high investor interest and potential volatility in the stock [1][2]. Financing Summary - On November 5, Junshi Biosciences had a financing buy-in amount of 39.95 million yuan, with a net buy of 572,900 yuan after repayments [1]. - The total margin financing and securities lending balance reached 1.404 billion yuan, with the financing balance accounting for 4.68% of the circulating market value, indicating a high level of leverage compared to the past year [1]. - The company’s financing balance of 1.391 billion yuan is above the 90th percentile of the past year, suggesting strong investor confidence [1]. Securities Lending Summary - On the same day, Junshi Biosciences repaid 4,500 shares in securities lending while selling 600 shares, with a total selling amount of 23,300 yuan based on the closing price [1]. - The remaining securities lending balance was 32,710 shares, with a total value of 12.697 million yuan, also exceeding the 90th percentile of the past year [1]. Company Overview - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2]. - As of September 30, 2025, the company reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% increase in losses [2]. - The number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2].

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of the company [5][6]. Core Insights - The company's core product, Toripalimab, has shown significant sales growth, with revenue reaching approximately 1.495 billion yuan in the first three quarters of 2025, a year-on-year increase of about 40% [3]. - The company continues to expand its research and development efforts, with R&D investment reaching 982 million yuan in the first three quarters of 2025, a year-on-year increase of 12.34% [4]. - The company has a strong cash reserve of 3.27 billion yuan as of the end of Q3 2025, indicating sufficient funding for ongoing projects [4]. Financial Performance Summary - For the first three quarters of 2025, the company reported total revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was a loss of 596 million yuan, a reduction in loss by 331 million yuan compared to the previous year [2]. - The third quarter alone saw revenue of 637 million yuan, a year-on-year increase of 31.40%, with a net profit loss of 183 million yuan [2]. Revenue and Profit Forecast - The company has adjusted its net profit forecasts for 2025 and 2026 to losses of 890 million yuan and 290 million yuan, respectively, while projecting a profit of 98 million yuan in 2027 [5]. - Revenue projections for the upcoming years are as follows: 2.595 billion yuan in 2025, 3.304 billion yuan in 2026, and 4.120 billion yuan in 2027, with growth rates of 33.18%, 27.32%, and 24.70% respectively [6]. R&D Pipeline and Approvals - The company is advancing multiple late-stage pipeline projects, including a first-in-class anti-BTLA monoclonal antibody and an anti-IL-17A monoclonal antibody, with significant clinical trial progress [4]. - The company has received regulatory approval for several new indications for Toripalimab, including a recent application for treating HER2-expressing urothelial carcinoma [3].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | | 1 RMB | | 260,295,700 | | ...